Imagotype
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, <i>EGFR</i>-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. | Publicación